(Q48247681)

9 February 2018

editorial

0 references

title

Understanding depression: linking brain-derived neurotrophic factor, transglutaminase 2 and serotonin. (English)

1 reference

9 February 2018

author name string

Kenji Hashimoto

series ordinal

1

1 reference

9 February 2018

publication date

1 January 2013

1 reference

9 February 2018

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

published in

1 reference

9 February 2018

volume

13

1 reference

9 February 2018

issue

1

1 reference

9 February 2018

page(s)

5-7

1 reference

9 February 2018

Emerging role of glutamate in the pathophysiology of major depressive disorder.

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

BDNF variant linked to anxiety-related behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Tissue transglutaminase: a possible role in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Transglutaminases and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Transglutaminase-catalyzed post-translational modifications of proteins in the nervous system and their possible involvement in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Cysteamine attenuates the decreases in TrkB protein levels and the anxiety/depression-like behaviors in mice induced by corticosterone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Phospholipase C, Ca2+, and calmodulin signaling are required for 5-HT2A receptor-mediated transamidation of Rac1 by transglutaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

Ketamine for depression: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.12.140

21 January 2018

Identifiers

DOI

10.1586/ERN.12.140

1 reference

9 February 2018

1 reference

9 February 2018